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BACKGROUND
X-linked hypophosphatemia is characterized by increased secretion of fibroblast growth 
factor 23 (FGF-23), which leads to hypophosphatemia and consequently rickets, osteoma-
lacia, and skeletal deformities. We investigated burosumab, a monoclonal antibody that 
targets FGF-23, in patients with X-linked hypophosphatemia.
METHODS
In an open-label, phase 2 trial, we randomly assigned 52 children with X-linked hypo-
phosphatemia, in a 1:1 ratio, to receive subcutaneous burosumab either every 2 weeks or 
every 4 weeks; the dose was adjusted to achieve a serum phosphorus level at the low end 
of the normal range. The primary end point was the change from baseline to weeks 40 
and 64 in the Thacher rickets severity total score (ranging from 0 to 10, with higher scores 
indicating greater disease severity). In addition, the Radiographic Global Impression of 
Change was used to evaluate rachitic changes from baseline to week 40 and to week 64. 
Additional end points were changes in pharmacodynamic markers, linear growth, physi-
cal ability, and patient-reported outcomes and the incidence of adverse events.
RESULTS
The mean Thacher rickets severity total score decreased from 1.9 at baseline to 0.8 at week 
40 with every-2-week dosing and from 1.7 at baseline to 1.1 at week 40 with every-4-week 
dosing (P<0.001 for both comparisons); these improvements persisted at week 64. The 
mean serum phosphorus level increased after the first dose in both groups, and more than 
half the patients in both groups had levels within the normal range (3.2 to 6.1 mg per 
deciliter [1.0 to 2.0 mmol per liter]) by week 6. Stable serum phosphorus levels were main-
tained through week 64 with every-2-week dosing. Renal tubular phosphate reabsorption 
increased from baseline in both groups, with an overall mean increase of 0.98 mg per 
deciliter (0.32 mmol per liter). The mean dose of burosumab at week 40 was 0.98 mg per 
kilogram of body weight with every-2-week dosing and 1.50 mg per kilogram with every-
4-week dosing. Across both groups, the mean serum alkaline phosphatase level decreased 
from 459 U per liter at baseline to 369 U per liter at week 64. The mean standing-height 
z score increased in both groups, with greater improvement seen at all time points with 
every-2-week dosing (an increase from baseline of 0.19 at week 64) than with every-4-week 
dosing (an increase from baseline of 0.12 at week 64). Physical ability improved and pain 
decreased. Nearly all the adverse events were mild or moderate in severity.
CONCLUSIONS
In children with X-linked hypophosphatemia, treatment with burosumab improved renal 
tubular phosphate reabsorption, serum phosphorus levels, linear growth, and physical 
function and reduced pain and the severity of rickets. (Funded by Ultragenyx Pharmaceu-
tical and Kyowa Hakko Kirin; ClinicalTrials.gov number, NCT02163577; EudraCT number, 
2014-000406-35).
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X-linked hypophosphatemia, a dis-order of renal phosphate wasting and the most common heritable form of rickets, 
is caused by loss-of-function mutations in the 
gene encoding phosphate-regulating endopepti-
dase homolog X-linked (PHEX), which results in 
excess circulating fibroblast growth factor 23 
(FGF-23).1 FGF-23 is the primary regulator of 
phosphate homeostasis and acts by controlling 
phosphate reabsorption in the kidney.2 Excess 
FGF-23 impairs renal phosphate reabsorption, 
which leads to hypophosphatemia, and decreases 
the synthesis of the active metabolite of vita-
min D, 1,25-dihydroxyvitamin D (also known as 
1,25[OH]2D). Chronic hypophosphatemia leads 
to rickets and osteomalacia, which often result 
in stunted growth, lower-limb deformity, pain, 
and physical dysfunction that can limit daily 
activities.1,3-5
Conventional therapy for X-linked hypophos-
phatemia consists of multiple daily doses of oral 
phosphate salts and vitamin D metabolites or 
analogues as replacement therapy.6 This treat-
ment, which has been in place for approximately 
four decades, transiently increases serum phos-
phorus levels; however, it is associated with 
incomplete healing of rickets, residual skeletal 
deformity, persistent short stature, gastrointesti-
nal side effects, and risks of metabolic and en-
docrine abnormalities such as hypercalciuria, 
nephrocalcinosis, and hyperparathyroidism.1,5,7-12
Burosumab is a recombinant human IgG1 
monoclonal antibody that targets FGF-23.13,14 In 
phase 1 and 2 trials involving adults with X-linked 
hypophosphatemia, treatment with burosumab, 
administered at doses of up to 1 mg per kilo-
gram of body weight every 4 weeks, improved 
renal tubular phosphate reabsorption, thereby 
increasing serum phosphorus to normal levels, 
and increased serum 1,25-dihydroxyvitamin D 
levels.13-15 Here, we report the results of a clinical 
trial that evaluated the efficacy and safety of 
burosumab in pediatric patients with X-linked 
hypophosphatemia.
Me thods
Patients
Children between 5 and 12 years of age were 
eligible for participation if they had received a 
diagnosis of X-linked hypophosphatemia; if they 
had active rickets at growth plates, bowing of 
the femur or tibia, or both; and if their pubertal 
stage was classified as Tanner stage 2 or lower 
(with stages ranging from 1 to 5 and higher 
stages indicating more advanced pubertal devel-
opment). X-linked hypophosphatemia was con-
firmed either by the presence of the PHEX muta-
tion in the patient or a directly related family 
member or by a serum intact FGF-23 level of 
more than 30 pg per milliliter.16,17 Additional in-
clusion criteria were a fasting serum phosphorus 
level of 2.8 mg or less per deciliter (0.90 mmol 
per liter) and a standing height below the 50th 
percentile for age and sex on the basis of local 
normative data from the United States or Europe. 
After the initial 36 patients were enrolled, an-
other 16 patients were enrolled to provide addi-
tional safety and efficacy data. The 16 additional 
patients were required to have a Thacher rickets 
severity total score of at least 1.5 at the knee.18 
Thacher rickets severity total score ranges from 
0 (no rickets) to 10 (severe rickets); scores be-
tween 0 and 5 are typically observed in children 
with the form of rickets assessed in this trial. 
All the participants discontinued the conven-
tional therapy they were receiving for X-linked 
hypophosphatemia for the duration of the trial. 
Key exclusion criteria were the use of vitamin D 
metabolites or analogues within 14 days before 
screening; the use of oral phosphate supple-
ments, aluminum hydroxide antacids, systemic 
glucocorticoids, or thiazide diuretics within 7 days 
before screening; the use of growth hormone 
therapy within 3 months before screening; neph-
rocalcinosis of grade 3 or higher as assessed by 
renal ultrasonography19; hypocalcemia or hyper-
calcemia; tertiary hyperparathyroidism as deter-
mined by the investigator; or the use of calcimi-
metic agents within 2 months before screening.
Trial Design
In this randomized, open-label, parallel-group, 
phase 2 trial, we investigated the efficacy and 
safety of burosumab in children with X-linked 
hypophosphatemia at nine sites in the United 
States and Europe (see the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org). Patients were randomly assigned, 
in a 1:1 ratio, to receive burosumab subcutane-
ously every 2 weeks or every 4 weeks during a 
16-week dose-escalation period, followed by a 
48-week treatment period, for a total of 64 weeks 
of treatment. Patients had the option to enroll in 
A Quick Take 
is available at 
NEJM.org
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an open-label extension. Enrollment of the initial 
36 patients could include no more than 20 boys 
or 20 girls.
After the initial doses of burosumab (0.1 mg 
per kilogram every 2 weeks or 0.2 mg per kilo-
gram every 4 weeks) were administered and no 
severe side effects were observed, patients were 
assigned sequentially to receive escalating doses 
(0.2 or 0.3 mg per kilogram every 2 weeks, or 0.4 
or 0.6 mg per kilogram every 4 weeks). During 
the dose-escalation period, the dose was adjusted 
according to the patient’s fasting serum phos-
phorus level 2 weeks after administration, with 
a goal of attaining a phosphorus level at the low 
end of the normal range (see the Supplementary 
Appendix).
Trial End Points
The primary end point was the change from 
baseline (with baseline scores determined ac-
cording to radiographs obtained at screening) to 
week 40 and week 64 in the Thacher rickets se-
verity total score, as determined by an indepen-
dent central reader who was unaware of the 
treatment assignments; scores reflected com-
bined assessments of prespecified radiographic 
abnormalities at the wrist and knee.18 In addi-
tion, the Radiographic Global Impression of 
Change was used to evaluate rachitic changes 
from baseline to week 40 and to week 64; three 
radiologists who were unaware of the treatment 
assignments each provided scores, which were 
subsequently averaged. The Radiographic Global 
Impression of Change scale is a tool that enables 
a side-by-side comparison of radiographs obtained 
before and after treatment and is based on a 
7-point ordinal scale that ranges from 3 (com-
plete healing) to −3 (severe worsening). An as-
sessment of deformities of the legs was also 
performed with the use of the Radiographic 
Global Impression of Change scale.20
Secondary end points included the change 
from baseline in the following pharmacody-
namic variables: the renal tubular phosphate 
reabsorption (expressed as the ratio of the 
maximum rate of tubular reabsorption of phos-
phate to the glomerular filtration rate), the 
serum phosphorus level, the serum 1,25-dihy-
droxyvitamin D level, and the serum alkaline 
phosphatase level (a marker of rachitic activity); 
all serum and urine samples for these assess-
ments were obtained during fasting.18,21-24 Addi-
tional details of the trial methods and the timing 
of assessments are available in the Supplemen-
tary Text section and Table S1 in the Supplemen-
tary Appendix. We also assessed the height-for-
age z score, physical ability (as evaluated with 
the use of the 6-minute walk test), and patient-
reported pain and functional disability (as mea-
sured with the use of the Pediatric Orthopedic 
Society of North America Pediatric Outcomes 
Data Collection Instrument; normative scores 
range from 0 to 100, with higher scores indicat-
ing better functioning or less pain).25-27
All reported adverse events and serious ad-
verse events were tabulated. Changes in levels of 
serum calcium and serum intact parathyroid 
hormone and in urinary excretion of calcium 
were determined. Urinary phosphorus was mea-
sured to calculate the ratio of the maximum rate 
of tubular reabsorption of phosphate to the glo-
merular filtration rate. Serial assessments of the 
development of both immunoreactive and neutral-
izing antibodies to burosumab were performed. 
Evidence of ectopic calcification was evaluated 
by renal and cardiac ultrasonography.19
Trial Oversight
The institutional review board at each partici-
pating site approved the protocol, available at 
NEJM.org. Parents or guardians provided writ-
ten informed consent for their children to par-
ticipate, and when age-appropriate, the patient’s 
assent was obtained before participation. An 
external data and safety monitoring committee 
monitored patient safety. The trial investigators 
and the sponsors, Ultragenyx Pharmaceutical and 
Kyowa Hakko Kirin, designed the trial and col-
lected, analyzed, and interpreted the data. The 
authors made the decision to submit the manu-
script for publication and vouch for the com-
pleteness and accuracy of the data and for the 
fidelity of the trial to the protocol. The manu-
script was written by the authors with medical 
writing support from the sponsors.
Statistical Analysis
For all the analyses of pharmacodynamic mark-
ers, P values were calculated for the mean change 
from baseline to week 40 with the use of paired 
Student’s t-tests. For the analysis of the Thacher 
rickets severity total score, we calculated P values 
and 95% confidence intervals for the least-squares 
mean change from baseline to week 40 using 
The New England Journal of Medicine 
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the generalized estimating equation approach, 
which included regimen, trial visit, baseline 
Thacher rickets severity total score, and the inter-
action between regimen and trial visit as categor-
ical variables, with an exchangeable covariance 
structure. All other assessments were reported 
as means and standard deviations, least-squares 
means and standard errors, or changes from 
baseline. For the analyses of the Thacher rickets 
severity total score, serum phosphorus level, renal 
tubular phosphate reabsorption, 1,25-dihydroxy-
vitamin D level, and serum alkaline phosphatase 
level, P values for the mean change from base-
line in each dosing group at week 40 are pre-
sented as nominal P values.
We estimated that a sample of 50 patients 
would provide the trial with at least 90% power 
to detect a mean (±SD) change from baseline of 
0.5±0.5 in the Thacher rickets severity total 
score. Nominal two-sided P values of 0.05 or less 
were considered to indicate statistical signifi-
cance.
R esult s
Patients
A total of 79 children were screened, of whom 
52 (66%) were eligible for participation and were 
randomly assigned to receive burosumab either 
every 2 weeks or every 4 weeks (26 patients in 
each group). All 52 patients completed 64 weeks 
of treatment, were included in the efficacy and 
safety analyses, and continued into the exten-
sion period.
Overall, the demographic and clinical charac-
teristics of the two groups were similar at base-
line, although standing height was slightly great-
er in the every-2-week dosing group (Table 1). At 
baseline, patients had persistent rickets, bowing 
of the femur or tibia, or both, as well as short 
stature, even though 96% had received previous 
conventional therapy for X-linked hypophospha-
temia for a mean of 6.9 years. At baseline, 94% 
of the patients had active rickets at growth plate 
sites (Thacher rickets severity total score >0). 
Baseline radiographs revealed that many patients 
had metaphyseal abnormalities at the distal fe-
mur (lucency, 98%; separation, 100%; fraying, 
89%; and concavity, 89%), proximal tibia (lu-
cency, 89%; separation, 85%; fraying, 67%; and 
concavity, 79%), distal ulna (lucency, 85%; sepa-
ration, 73%; fraying, 54%; and concavity, 83%), 
and distal radius (lucency, 60%; separation, 50%; 
fraying, 35%; and concavity, 39%).
Efficacy
By week 40, rickets was significantly ameliorated, 
with a mean Thacher rickets severity total score 
of 0.8 in the every-2-week dosing group and 1.1 
in the every-4-week dosing group (least-squares 
mean change, −1.1 with every-2-week dosing and 
−0.7 with every-4-week dosing; P<0.001 for both 
comparisons) (Fig. 1A, and Table S2 in the Sup-
plementary Appendix); these improvements were 
maintained at week 64. The reductions in the 
Thacher rickets severity total score were greater 
among the 34 patients who had a Thacher rickets 
severity total score of 1.5 or higher at baseline, 
with a least-squares mean change at week 40 
of −1.7 with every-2-week dosing and −1.3 with 
every-4-week dosing (Fig. 1A, and Table S3 in 
the Supplementary Appendix).
The Radiographic Global Impression of Change 
global score at week 40 also indicated reduction 
in the severity of rickets with both dosing regi-
mens (Fig. 1B, and Table S2 in the Supplemen-
tary Appendix). Substantial healing of rickets 
(change from baseline represented by a score of 
≥2.0) was achieved in 28 of 52 patients (54%) at 
week 40 (18 of 26 patients in the every 2-week-
dosing group and 10 of 26 patients in the every-
4-week dosing group) and also in 28 of 52 pa-
tients (54%) at week 64 (15 of 26 patients in the 
every 2-week-dosing group and 13 of 26 patients 
in the every-4-week dosing group). Among the 
17 patients who had a Thacher rickets severity 
total score of 1.5 or higher at baseline and were 
receiving burosumab every 2 weeks, 16 patients 
(94%) showed substantial healing at week 40 
(Fig. 1B, and Table S3 in the Supplementary Ap-
pendix). Furthermore, when the Radiographic 
Global Impression of Change scale was used to 
assess overall deformities of the legs, a modest 
improvement was observed at week 64 in all 52 
patients (mean [±SE] score representative of 
change, 0.5±0.1).
The mean fasting serum phosphorus level 
increased from baseline in both groups at all 
time points, with an overall mean increase of 
0.75 mg per deciliter (0.24 mmol per liter; a 34% 
increase) (Fig. 2A) at week 40 and 0.84 mg per 
deciliter (0.27 mmol per liter; a 38% increase) at 
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Characteristic
Burosumab 
Every 2 Weeks 
(N = 26)
Burosumab 
Every 4 Weeks 
(N = 26)
All Patients 
(N = 52)
Age — yr
Mean 8.7±1.7 8.3±2.0 8.5±1.9
Range 5–12 5–12 5–12
Male sex — no. (%) 12 (46) 12 (46) 24 (46)
White race — no. (%)† 23 (88) 23 (88) 46 (88)
Weight — kg 31.9±7.9 29.1±10.7 30.5±9.4
Standing height
z Score −1.7±1.0 −2.1±1.0 −1.9±1.00
Percentile for age and sex 11.1±13.8 6.2±8.2 8.7±11.5
Geographic region — no. (%)
United States 17 (65) 19 (73) 36 (69)
Europe 9 (35) 7 (27) 16 (31)
Previous conventional therapy for X-linked hypophos-
phatemia — no. (%)
24 (92) 26 (100) 50 (96)
Duration of conventional therapy — yr 7.0±2.1 6.7±2.6 6.9±2.4
Age when conventional therapy was initiated — yr 2.2±1.5 1.9±1.2 2.1±1.3
Renal tubular phosphate reabsorption — mg/dl‡§ 2.2±0.5 2.0 ±0.3 2.1±0.4
Serum phosphorus — mg/dl§ 2.4±0.4 2.3±0.3 2.3±0.4
Serum 1,25-dihydroxyvitamin D — pg/ml§ 41.3±22.0 41.4±15.3 41.3±18.7
Serum alkaline phosphatase — U/liter§ 462±110 456±101 459±105
Thacher rickets severity total score¶
Mean 1.9±1.2 1.7±1.0 1.8±1.1
Range 0–4.5 0–3.0 0–4.5
Positive for pathogenic PHEX mutation — no. (%)‖ 23 (88) 22 (85) 45 (87)
Nephrocalcinosis grade — no. (%)**
0 17 (65) 17 (65) 34 (65)
1 6 (23) 5 (19) 11 (21)
2 3 (12) 4 (15) 7 (13)
*  Plus–minus values are means ±SD. To convert the values for renal tubular phosphate reabsorption to millimoles per 
liter, multiply by 0.3229. To convert the values for serum phosphorus to millimoles per liter, multiply by 0.3229. To 
convert the values for serum 1,25-dihydroxyvitamin D to picomoles per liter, multiply by 2.6. Percentages may not 
sum to 100 because of rounding.
†  Race was determined by parent or caregiver report.
‡  Renal tubular phosphate reabsorption is expressed as the ratio of the maximum rate of tubular reabsorption of phos-
phate to the glomerular filtration rate.
§  Serum and urine samples for pharmacodynamic assessments were obtained during fasting.
¶  The baseline mean Thacher rickets severity total score (scores range from 0 [no rickets] to 10 [severe rickets]; scores 
between 0 and 5 are typically observed in children with the form of rickets assessed in this trial) for the 16 patients 
who enrolled after enrollment of the initial 36 patients was 2.63±0.72.
‖  One patient had a variant in PHEX that was considered to be probably pathogenic, and four patients had variants in 
PHEX of unknown significance. No mutation in PHEX was identified in two patients; however, the analysis of muta-
tions in PHEX cannot capture all possible mutations that alter PHEX activity. The seven patients who were not posi-
tive for pathogenic mutations in PHEX had a clinical diagnosis of X-linked hypophosphatemia and had a baseline se-
rum intact FGF-23 level of more than 30 pg per milliliter.
**  Values range from 0 (normal) to 4 (stone formation).
Table 1. Demographic and Baseline Clinical Characteristics.*
The New England Journal of Medicine 
Downloaded from nejm.org at Washington University in St. Louis Becker Library on May 29, 2018. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 378;21 nejm.org May 24, 20181992
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
week 64. By week 6, more than half the patients 
in both groups had serum phosphorus levels 
within the normal range (3.2 to 6.1 mg per deci-
liter [1.0 to 2.0 mmol per liter]). Every-2-week 
dosing was associated with sustained mean in-
creases in serum phosphorus levels during the 
treatment period, whereas every-4-week dosing 
showed fluctuations over time. No patients in ei-
ther group had a serum phosphorus level above 
the upper limit of the normal range at any time 
during the trial.
The renal tubular phosphate reabsorption in-
creased from baseline in both groups at all time 
points, with an overall mean increase of 0.98 mg 
per deciliter (0.32 mmol per liter; a 51% increase) 
(Fig. 2B) at week 40 and 1.01 mg per deciliter 
(0.33 mmol per liter; a 51% increase) at week 64. 
The mean serum 1,25-dihydroxyvitamin D level 
increased from baseline in both groups at all 
time points, with an overall mean increase of 
23 pg per milliliter (60 pmol per liter; a 99% 
increase) (Fig. 2C) at week 40 and 18 pg per milli-
liter (46 pmol per liter; a 78% increase) at week 64. 
The mean serum alkaline phosphatase level de-
creased from baseline by 90 U per liter overall at 
week 64 (a 20% decrease) (Fig. 2D).
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The mean standing-height z score increased 
from baseline in both groups, with greater im-
provement seen at all time points with every-
2-week dosing (an increase from baseline of 0.19 
at week 64) than with every-4-week dosing (an 
increase from baseline of 0.12 at week 64). Re-
sults are shown in Table 2, and in Figure S2A in 
the Supplementary Appendix.
Across both groups, walking distance in the 
6-minute walk test was increased from baseline 
both at week 40 and at week 64 (Table 2). A total 
of 24 of the 52 patients (46%) had an impair-
ment (defined as a walking distance that was 
<80% of the predicted normal distance) at base-
line. Among these patients, the 6-minute walk 
test distance increased from 68% of the pre-
dicted normal distance (408 m) at baseline to 
79% of the predicted distance (487 m) at week 
64 (an increase of 10%; least-squares mean in-
crease in distance walked, 77 m); greater increas-
es were seen among the 14 patients who received 
the drug every 2 weeks (12% increase; least-
squares mean increase in distance walked, 96 m) 
than among the 10 patients who received the 
drug every 4 weeks (8% increase; least-squares 
mean increase in distance walked, 58 m) (Fig. 
S2B in the Supplementary Appendix).
The baseline mean scores for the sports and 
physical functioning domain and the pain and 
comfort domain of the Pediatric Outcomes Data 
Collection Instrument were low, defined as less 
than 1 SD below the normal population mean.28 
Functional ability improved and pain decreased 
in both groups (Table 2). Among the 28 patients 
(54% of the 52 patients) who had greater func-
tional impairment (defined as a score of <40 on 
the Global Functioning Scale) at baseline, the 
score on the sports and physical functioning 
domain increased by a mean of 15.6 at week 64, 
and the score on the pain and comfort domain 
increased by a mean of 13.4 at week 64. The re-
sults for the upper extremity, transfer and basic 
mobility, and happiness domains are described 
in the Supplementary Appendix.
Safety
Adverse events were reported in all 52 patients 
(Table 3). One patient who received burosumab 
every 4 weeks was hospitalized for serious ad-
verse events of fever and myalgia, both of which 
were assessed as being moderate in severity and 
possibly related to burosumab. The fever resolved 
within 24 hours after onset, the myalgia resolved 
within 8 days, and the patient continued to re-
ceive treatment without recurrence of a similar 
event. A total of 17 of the 26 patients (65%) in 
the every-2-week dosing group and 13 of the 26 
patients (50%) in the every-4-week dosing group 
had an injection-site reaction; these reactions 
were considered to be mild, were limited to the 
skin, and lasted no more than 1 or 2 days. 
Other common adverse events across the two 
dosing groups were headache (26 patients), cough 
(23 patients), nasopharyngitis (21 patients), and 
pain in an arm or leg (21 patients). No patients 
died, discontinued the trial regimen, or had dose-
limiting toxic effects. All adverse events reported 
during the trial were mild or moderate in severity, 
with the exception of a tooth abscess (in 1 pa-
tient) and a rash (in 1 patient); both events were 
considered by the investigator to be unrelated to 
the trial treatment.
No noteworthy changes in the levels of serum 
Figure 1 (facing page). Effects of Burosumab on Rickets 
Scores.
Panel A shows the mean Thacher rickets severity total 
score (scores range from 0 [no rickets] to 10 [severe 
rickets]; scores between 0 and 5 are typically observed 
in children with the form of rickets assessed in this trial). 
All 52 patients were included in the analyses at week 
40 and at week 64. A significant decrease in the Thacher 
rickets severity total score was seen at week 40 in both 
dosing groups (P<0.001) on the basis of the generalized 
estimating equation model. Panel B shows the least-
squares mean Radiographic Global Impression of Change 
score (representing the degree of change from baseline) 
at week 40 and week 64. The Radiographic Global Im-
pression of Change scale is a tool that enables a side-
by-side comparison of radiographs obtained before 
and after treatment and is based on a 7-point ordinal 
scale: 3 (complete healing), 2 (substantial healing), 1 
(minimal healing), 0 (unchanged), −1 (minimal worsen-
ing), −2 (moderate worsening), and −3 (severe worsen-
ing). Scores for the Thacher rickets severity total score 
and the Radiographic Global Impression of Change are 
shown for all patients and for the subgroup of patients 
who had a Thacher rickets severity total score of 1.5  
or higher at baseline (indicating more severe rickets).  
I bars in Panels A and B indicate standard errors. Panel C 
shows a set of radiographs of the knee from an 11-year- 
old girl who had been receiving conventional therapy 
for 9 years before she was enrolled in the trial and was 
randomly assigned to receive burosumab every 2 weeks. 
The baseline image shows metaphyseal lucencies of 
the distal femur and proximal tibia. By week 64, the ab-
normalities were completely healed (Thacher rickets 
severity total score of 0). The Radiographic Global Im-
pression of Change score for the knee at week 64 was 
2.3, which indicated substantial healing of rickets.
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Assessment
Burosumab 
Every 2 Weeks 
(N = 26)
Burosumab 
Every 4 Weeks 
(N = 26)
All Patients 
(N = 52)
Standing-height z score*
Baseline −1.72±1.03 −2.05±0.96 −1.89±1.00
Week 64 −1.54±1.13 −1.92±0.84 −1.73±1.00
Change from baseline 0.19±0.05 0.12±0.06 0.15±0.04
6-Minute walk test†
Baseline
Percentage of predicted distance 79.32±2.60 81.42±2.96 80.37±1.96
Distance (m) 479.9±16.6 486.4±21.3 483.1±13.4
Week 64
Percentage of predicted distance 85.00±2.03 84.74±2.67 84.87±1.66
Change from baseline in percentage of predicted 
distance — percentage points
5.69±2.02 3.32±1.96 4.50±1.41
Distance (m) 533.85±11.51 525.85±17.56 529.85±10.41
Change from baseline in distance (m) 52.67±8.82 40.59±9.57 46.63±6.48
Sports and physical functioning, normative score*‡
Baseline 34.6±15.7 32.2±19.3 33.4±17.4
Week 64 41.7±15.7 42.8±13.7 42.2±14.6
Change from baseline 7.7±2.6 9.8±2.5 8.8±1.8
Pain and comfort scale, normative score*‡
Baseline 35.2±15.3 34.8±16.8 35.0±15.9
Week 64 41.0±17.0 43.0±11.5 42.0±14.5
Change from baseline 5.6±2.9 7.7±2.1 6.7±1.8
Global functioning, normative score*‡
Baseline 37.5±14.0 35.6±17.2 36.6±15.5
Week 64 43.1±16.1 45.1±11.2 44.1±13.8
Change from baseline 6.0±2.7 8.7±2.0 7.4±1.7
*  Plus–minus values at baseline and at week 64 are means ±SD. Plus–minus values for the change from baseline are 
least-squares means ±SE.
†  Plus–minus values for the percentage of predicted distance and for distance are means ±SE. Plus–minus values for the 
change from baseline are least-squares means ±SE.
‡  This variable was assessed with the use of the Pediatric Orthopedic Society of North America Pediatric Outcomes Data 
Collection Instrument. The mean (±SD) population normative score is 50±10; higher scores indicate better functioning 
or less pain.
Table 2. Effects of Burosumab on Height, Physical Functioning, and Patient-Reported Outcomes.
Figure 2 (facing page). Effects of Burosumab on Pharmacodynamic Variables.
All serum and urine samples were obtained during fasting. A significant mean increase from baseline to week 40  
in serum phosphorus level (Panel A), the renal tubular phosphate reabsorption (expressed as the ratio of the maxi-
mum rate of tubular reabsorption of phosphate to the glomerular filtration rate) (Panel B), and serum 1,25-dihydroxy-
vitamin D level (Panel C) was seen among the 26 patients in each group (P<0.001). With respect to the serum alka-
line phosphatase level (Panel D), there was a significant mean decrease from baseline to week 40 with every-2-week 
dosing (26 patients, P<0.001) and with every-4-week dosing (26 patients, P = 0.002). Graphs displayed in SI units are 
available in Figure S5 in the Supplementary Appendix. The reference range for serum alkaline phosphatase was pro-
vided by Covance Laboratories, and the reference ranges for the remaining variables were obtained from published 
articles: serum phosphorus, from Lockitch et al.24; renal tubular phosphate reabsorption, from Kruse et al.23; and 
1,25-dihydroxyvitamin D, from Chesney et al.22 I bars indicate standard errors.
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calcium, urinary calcium, or serum intact para-
thyroid hormone were observed (Figs. S3 and S4 
in the Supplementary Appendix), and no notable 
changes in vital signs occurred. Mild elevations 
in serum amylase levels, primarily the salivary 
isoenzyme, were detected in 13 patients at screen-
ing and in 26 patients during at least one of nine 
total assessments through week 64. None of the 
elevations were associated with symptoms. Eval-
uation of renal ultrasonographic images to de-
tect nephrocalcinosis revealed no change from 
baseline in renal ultrasound scores (0 [normal] 
to 4 [stone formation]19,29) in 21 patients in each 
group; of the remaining patients, 1 patient in 
each group had a decrease in score from 1 to 0 
and 3 patients in each group had an increase in 
score from 0 to 1, 1 to 2, or 2 to 3. Ultrasono-
graphic data from 2 patients were missing. No 
patient had a change in renal ultrasound score 
of more than 1 point. Renal function remained 
normal. There was no evidence of ectopic myo-
cardial mineralization on echocardiography. No 
antibodies to burosumab were detected at any 
postbaseline visits. The mean dose of burosumab 
at week 40 was 0.98 mg per kilogram with every-
2-week dosing and 1.50 mg per kilogram with 
every-4-week dosing.
Discussion
In the current trial, inhibition of FGF-23 activity 
with burosumab, a recombinant human IgG1 
monoclonal antibody, was associated with an 
increase in renal tubular phosphate reabsorption 
Variable
Burosumab 
Every 2 Weeks 
(N = 26)
Burosumab 
Every 4 Weeks 
(N = 26)
All Patients 
(N = 52)
no. of patients (%)
Any adverse event 26 (100) 26 (100) 52 (100)
Adverse events with ≥15% incidence in both 
groups combined
Injection-site reaction* 17 (65.4) 13 (50.0) 30 (57.7)
Headache 16 (61.5) 10 (38.5) 26 (50.0)
Cough 15 (57.7) 8 (30.8) 23 (44.2)
Nasopharyngitis 8 (30.8) 13 (50.0) 21 (40.4)
Pain in extremity 9 (34.6) 12 (46.2) 21 (40.4)
Upper respiratory tract infection 9 (34.6) 9 (34.6) 18 (34.6)
Vomiting 10 (38.5) 8 (30.8) 18 (34.6)
Arthralgia 7 (26.9) 10 (38.5) 17 (32.7)
Pyrexia 8 (30.8) 8 (30.8) 16 (30.8)
Rash 7 (26.9) 6 (23.1) 13 (25.0)
Seasonal allergy 5 (19.2) 8 (30.8) 13 (25.0)
Abdominal pain, upper 4 (15.4) 5 (19.2) 9 (17.3)
Oropharyngeal pain 3 (11.5) 6 (23.1) 9 (17.3)
Diarrhea 3 (11.5) 5 (19.2) 8 (15.4)
Nasal congestion 4 (15.4) 4 (15.4) 8 (15.4)
Nausea 5 (19.2) 3 (11.5) 8 (15.4)
Rhinorrhea 2 (7.7) 6 (23.1) 8 (15.4)
Serious adverse event 0 1 (3.8) 1 (1.9)
Leading to discontinuation of trial regimen 0 0 0
Resulting in death 0 0 0
Presence of antibody to burosumab 0 0 0
*  This category includes the following reactions at the injection site: erythema, swelling, rash, pruritus, bruising, pain, 
discoloration, hematoma, hemorrhage, macule, and urticaria.
Table 3. Adverse Events and Antibody Results.
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and the correction of hypophosphatemia in chil-
dren with X-linked hypophosphatemia. The im-
provement in phosphate metabolism correspond-
ed to a decrease in the severity of rickets. The 
healing of rickets probably contributed to con-
current improvements in growth and physical 
activity and a reduction in pain.
Treatment with burosumab administered once 
every 2 weeks provided a sustained increase in 
the serum phosphorus level to normal or near-
normal levels after the dose was adjusted to ap-
proximately 1 mg per kilogram, whereas every-
4-week dosing was associated with lower levels 
of serum phosphorus at the end of the dose in-
terval. Pharmacodynamic results showed a pla-
teaued treatment response, which suggested that 
feedback mechanisms may stabilize the levels of 
serum phosphorus and 1,25-dihydroxyvitamin D 
when the duration of exposure is longer or the 
dose levels are higher. Every-2-week dosing re-
sulted in substantial healing of rickets in nearly 
all the children who had more severe rickets at 
baseline. These results indicate that burosumab 
at a dose of approximately 1.0 mg per kilogram 
administered every 2 weeks is an appropriate 
regimen for improving renal tubular phosphate 
reabsorption and clinical outcomes in children 
with X-linked hypophosphatemia.
Small but significant amelioration of leg defor-
mity, as assessed by scores on the Radiographic 
Global Impression of Change, were observed. 
Studies in animals suggest that normalization of 
the ambient phosphate milieu may correct the 
disrupted cellular organization of the rachitic 
growth plate to allow for improved growth.30-33
In children with X-linked hypophosphatemia, 
ongoing management of the disease is critical to 
elicit the best possible skeletal outcomes; there-
fore, a placebo control group was deemed to be 
unacceptable, given the duration of the current 
trial. An active control group was not included 
in the trial owing to the lack of clinical data 
regarding burosumab or conventional therapy 
and to the considerable variability in the applica-
tion of conventional therapy.1 Despite the lack of 
a control group, the consistent improvement in 
the fasting serum phosphorus response that was 
observed in all the patients coincided with im-
provements in multiple related efficacy end points, 
including amelioration of rickets, increase in 
linear growth, improvement in physical ability, 
and reduction in pain. These findings suggest a 
therapeutic benefit in a pediatric population 
with X-linked hypophosphatemia in which almost 
all the patients had previously received conven-
tional therapy with limited clinical improve-
ment. On the basis of the findings from this 
trial, a phase 3 trial (ClinicalTrials.gov number, 
NCT02915705), which is ongoing, was designed 
to investigate the efficacy and safety of buro-
sumab as compared with conventional therapy.
No clinically significant safety findings with 
burosumab were observed during the current 
trial. The most commonly reported adverse 
events were either typical for children or were 
common manifestations of X-linked hypophos-
phatemia.1,34-38 Hyperphosphatemia was not ob-
served in any patient during treatment. More-
over, no noteworthy changes in levels of serum 
calcium, urinary calcium, or serum intact para-
thyroid hormone were noted, and no antibodies 
to burosumab were detected after treatment.
For more than 40 years, treatment for X-linked 
hypophosphatemia has consisted of multiple 
daily doses of oral phosphate salts and active 
vitamin D. This approach is often difficult to 
maintain, particularly in younger patients, owing 
to the burdens of multiple daily dosing, parental 
surveillance, and suboptimal phosphate prepa-
rations.5 The limitations of conventional therapy 
are evidenced by the persistence of rickets ob-
served in radiographs obtained at screening in 
this trial despite the patients having received 
therapy for X-linked hypophosphatemia at aca-
demic specialty centers for multiple years.1,5,6 By 
targeting a central pathophysiological defect in 
X-linked hypophosphatemia (i.e., excess FGF-23), 
burosumab improved phosphate homeostasis and 
decreased the severity of rickets.
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